Taysha Gene Therapies Inc. (TSHA)
TSHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.58
-13.53% on the day
Market cap
$1.2B
Small cap
Revenue · 2025
$9.8M
+17.3% on 2024
Net income · 2025
-$109.0M
-1115.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TSHA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001806310 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.8M |
| Net income | -$109.0M |
| Operating income | -$110.5M |
| Net margin | -1115.3% |
| Operating margin | -1130.6% |
| Revenue growth | +17.3% |
| Cash | $319.8M |
| Total assets | $343.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 119.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-25 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-08-11 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 401 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.9% |
| 1 month | -30.7% |
| 3 months | -41.3% |
| Year to date | -36.3% |
| 1 year | -30.6% |
| From 52-week high | -49.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| INBX | Inhibrx Biosciences Inc. | $87.08 | -3.81% | $1.3B |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
| COAG | Hemab Therapeutics Holdings Inc. | $29.80 | -1.94% | $1.4B |
| MGTX | MeiraGTx Holdings plc | $9.94 | -4.24% | $954.7M |
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
| MAZE | Maze Therapeutics Inc. | $26.66 | -3.75% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier